tbuckley/cabot-search huggingface dataset:
Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).
Authors: Andreas Hochhaus, Francis J. Giles, Philipp le Coutre, Michele Baccarani, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Gert Ossenkoppele, Franck Nicolini, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Jim Wang, Richard Woodman, Jorge Cortes, Hagop Kantarjian
Journal: Blood (2007)
FRI0208 Abatacept Therapy Combined with Tacrolimus for Rheumatoid Arthritis Patients Shows Superior Efficacy than Abatacept Therapy without Tacrolimus
Authors: A. Nampei, Y. Nagayama, H. Tsuboi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Abatacept (ABT) and tacrolimus (TAC) are similar at the point that both drugs block the T cell activation. ABT blocks co-stimulatory signaling from CD80/86 on the surface of antigen-presenting cell. TAC blocks the calcineurin activity in T cells. The each effectiveness of ABT and TAC respectively for the treatment of rheumatoid arthritis (RA) is apparent, however, the efficacy and safety at concomitant use of ABT and TAC was not unclear and there are few reports [1,2]. <h3>Objectives</h3> The objective of this study is comparison between ABT therapy for RA patients with and without TAC. <h3>Methods</h3> Forty eight RA patients were included in this observational retrospective study, who were undertaken intravenous ABT therapy at Osaka Rosai Hospital after February 2011 and could be observed over 52 weeks. Patient background, efficacy, and safety were examined. <h3>Results</h3> Mean age was 67.4 years, disease duration was 10.8 years. Concomitant use of methotrexate was 58%, of prednisolone was 56% and prior biologics use was 48%. Concomitant use of TAC was 31%. Mean tacrolimus dose was 2.0g (1.0–3.0). The retension rate of ABT at 52 weeks was 80.8%. DAS28CRP was decreased significantly at 4 weeks (-16.5% from baseline, p&lt;0.001), and gradually decreased until 24 weeks (-37.3%, p&lt;0.001) and maintained until 52weeks (-39.3%, p&lt;0.001) by Wilcoxon signed rank test. Patient background between ABT + TAC group (n=15) vs ABT group (n=33) were not significantly different (age, sex, disease duration, stage, class, concomitant use of prednisolone, MTX, prior biologics, baseline DAS28CRP, positivity of RF, ACPA) by chi-square test and Mann-Whitney U test. DAS28CRP of ABT + TAC group decreased significantly greater than ABT group at 16 weeks (-42.9% vs -30.3%, p=0.048), maintained until 52 weeks (-50.1% vs -34.5%, p=0.017) by Mann-Whitney U test. Adverse event between ABT + TAC and ABT group was not different. Predictive factor that achieve the low disease activity at 52weeks were Steinbrocker class1/2 (p=0.047), concomitant use of TAC (p=0.043) and DAS&lt;3.3 at 12 weeks (p=0.005) by multivariate logistic regression analysis. <h3>Conclusions</h3> ABT therapy concomitant with TAC has the possibility to show higher effectiveness for RA patients than ABT therapy without TAC. <h3>References</h3> Fujibayashi T. Mod Rheumatol 25: 825–30, 2015 Takahashi N. Rheumatol Int 35: 1707–16, 2015 <h3>Disclosure of Interest</h3> None declared
The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial
Authors: Patrick A. Zweidler-McKay, Daniel J. DeAngelo, Dan Douer, Hervé Dombret, Oliver G. Ottmann, Norbert Vey, Deborah A. Thomas, Lili Zhu, Fei Huang, Gaurav Bajaj, Bruce S. Fischer
Journal: Blood (2014)
Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies
Authors: Tanya Siddiqi, Anna Scuto, Jan H. Beumer, Joo Y. Song, Paul Frankel, Chris Ruel, Jacob Cobb, Brian F. Kiesel, Dennis D. Weisenburger, Kevin R. Kelly, Joseph Tuscano, Leslie Popplewell, Stephen J. Forman, Richard Piekarz, Edward M. Newman
Journal: Blood (2015)
An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe
Authors: David Ruttens, Stijn E. Verleden, Esmée M. Bijnens, Ellen Winckelmans, Jens Gottlieb, Gregor Warnecke, Federica Meloni, Monica Morosini, Wim Van Der Bij, Erik A. Verschuuren, Urte Sommerwerck, Gerhard Weinreich, Markus Kamler, Antonio Roman, Susana Gomez-Olles, Cristina Berastegui, Christian Benden, Are Martin Holm, Martin Iversen, Hans Henrik Schultz, Bart Luijk, Erik-Jan Oudijk, Johanna M. Kwakkel-van Erp, Peter Jaksch, Walter Klepetko, Nikolaus Kneidinger, Claus Neurohr, Paul Corris, Andrew J. Fisher, James Lordan, Gerard Meachery, Davide Piloni, Elly Vandermeulen, Hannelore Bellon, Barbara Hoffmann, Danielle Vienneau, Gerard Hoek, Kees de Hoogh, Benoit Nemery, Geert M. Verleden, Robin Vos, Tim S. Nawrot, Bart M. Vanaudenaerde
Journal: European Respiratory Journal (2016)

Air pollution from road traffic is a serious health risk, especially for susceptible individuals. Single-centre studies showed an association with chronic lung allograft dysfunction (CLAD) and survival after lung transplantation, but there are no large studies.13 lung transplant centres in 10 European countries created a cohort of 5707 patients. For each patient, we quantified residential particulate matter with aerodynamic diameter ≤10 µm (PM10) by land use regression models, and the traffic exposure by quantifying total road length within buffer zones around the home addresses of patients and distance to a major road or freeway.After correction for macrolide use, we found associations between air pollution variables and CLAD/mortality. Given the important interaction with macrolides, we stratified according to macrolide use. No associations were observed in 2151 patients taking macrolides. However, in 3556 patients not taking macrolides, mortality was associated with PM10 (hazard ratio 1.081, 95% CI 1.000-1.167); similarly, CLAD and mortality were associated with road lengths in buffers of 200-1000 and 100-500 m, respectively (hazard ratio 1.085- 1.130). Sensitivity analyses for various possible confounders confirmed the robustness of these associations.Long-term residential air pollution and traffic exposure were associated with CLAD and survival after lung transplantation, but only in patients not taking macrolides.
Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Authors: Loretta A. Williams, Hycienth Ahaneku, Jorge E. Cortes, Guillermo Garcia Manero, Hagop M. Kantarjian, Qiuling Shi, Huei-Kai Lin, Achala R. Limaye, Charles S. Cleeland
Journal: Blood (2014)
Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)
Authors: Aziz Nazha, Mikkael A. Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali, Gail J. Roboz, David P. Steensma, Amy E. DeZern, Cassie Zimmerman, Elias Jabbour, Molly D. Greenberg, Sangmin Lee, Alan F List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Rami S Komrokji
Journal: Blood (2014)
Combination Chemotherapy Using Cyclophosphamide and High Dose Dexamethasone with or without Radiotherapy for the Treatment of Multiple Myeloma.
Authors: Chul Soo Kim, Moon Hee Lee, Inho Kim, Yeonsook Moon, Chung Hyun Nahm, Hun Chung Kim, Woo Cheol Kim, John J.K. Loh
Journal: Blood (2005)
Benefit of routine histopathology testing for sleeve gastrectomy specimens
Authors: D. Dosani, R. Zakeri, S. Gupta, A. Alhamdani, P. Sufi, M. Howlader
Journal: International Journal of Surgery (2016)

Aim: To evaluate the outcomes of patients diagnosed with acute cholecystitis undergoing emergency laparoscopic cholecystectomy, versus medical management.This was done in the light of a growing body of evidence suggesting that urgent management is safe and effective in reducing duration of hospital stay and re-admission.Method: We collected data on patient demographics, length of stay, readmission rates, treatment offered and complication rates over a one year period and analysed in SPSS.A multivariate General Linear Model was used to determine the effect of independent patient variables (demographics, laboratory and imaging results), on outcome measures.Result: From a total of 250 admissions, 92 underwent emergency laparoscopic surgery.The average hospital stay was 4.1 days for emergency laparoscopic cholecystectomy versus 7.87 days for medically managed patients.Overall readmission rates were comparable between the patients treated with emergency laparoscopy and those medically managed, but interestingly, re-admission rates halved for the emergency laparoscopic cholecystectomy group who had their procedures done after 24hours but within one week of admission.Conclusion: Emergency cholecystectomy appears effective in reducing readmission rates when performed after the first 24 hours.Significant reduction in length of stay indicates that emergency cholecystectomy is cost effective in an NHS setting.
THU0092 Effect of Disease Modifying anti Rheumatic Drug Methotrexate on The Lipid Profile of Patients with Rheumatoid Arthritis
Authors: G.S. Sidhu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cardiovascular morbidity and mortality appear to be increased in rheumatoid arthritis (RA), which might be due to increased prevalence of risk factors for cardiovascular disease, such as an accelerated progression of atherosclerosis. Patients with active RA frequently show an atherogenic lipid profile, which has been linked with the inflammatory reaction. <h3>Objectives</h3> The AIM of this study is to determine the effect of treatment with methotrexate on the lipid profile of patients with rheumatoid arthritis. <h3>Methods</h3> We studied 25 patients with newly diagnosed rheumatoid arthritis who had not been treated with corticosteroids or disease-modifying antirheumatic drugs. We measured serum lipid profile of patients, who achieve remission according to DAS28 scores, at baseline and 3, 6 and 12 months post methotrexate to study the effect of the drug on the lipid levels. <h3>Results</h3> Twenty five patients were included in this prospective study 22 females (88%) and 3 males (12%). The mean age of patients was (46.40 ± 13.00). In these patients, mean high density lipoprotein (HDL) increased by 18.8 ± 11.3% (p&lt;0.001), 21.9 ± 12.5% (p&lt;0.001) and 26.8 ± 12.3% (p&lt;0.001) and total cholesterol (TC) increased by 16.39 ± 22.12% (p&lt;0.001), 14.38 ± 18.18% (p&lt;0.001) and 12.94 ± 16.81% (p&lt;0.001) at 3, 6, and moths respectively. Increase in Light density lipoprotein (LDL) was statistically significant at 3 months {9.89 ± 18.84% (p&lt;0.042)} where as significant decrease in the level of triglycerides was noted at 6 months 2.69 ± 3.94% (p&lt;0.003) and at 12 months2.62 ± 4.52% (p&lt;0.010). Despite the increase in HDL, LDL and TC the atherogenic ratios (TC/HDL and LDL/HDL ratios) showed improvement at 3, 6 and 12 months post MTX treatment. There was negative association between changes in DAS28(ESR) after 3 months therapy and changes in HDL, LDL and TC levels. <h3>Conclusions</h3> Lipid profile and atherogenic ratios (TC/HDL and LDL/HDL ratios) improves substantially following effective treatment with methotrexate of rheumatoid arthritis. This improvement may reduce the risk of cardiovascular disease. With a decline in disease activity, a rising trend was observed for all lipids. However, changes in disease activity (DAS28) were only significantly related to changes in HDL cholesterol and LDL cholesterol levels. <h3>Acknowledgement</h3> I dedicate this thesis to my beloved parents; my father Jeet Singh Sidhu and my mother Amarjit kaur. <h3>Disclosure of Interest</h3> G. sidhu Shareholder of: no, Grant/research support from: no, Consultant for: no, Employee of: no, Paid instructor for: no, Speakers bureau: no
P08.11 Lis1 is preferentially expressed in glioblastoma CD133+ cells and regulates the self-renewal and migration of U87 CD133+ cells
Authors: F. M. Brehar, A. V. Gafencu, D. Arsene, V. G. Trusca, E. V. Fuior, S. E. Mara Baez Rodriguez, M. Amairah, M. R. Gorgan
Journal: Neuro-Oncology (2016)

was 39% (95% CI 21-57).No significant correlation was found between clinical outcome measures and the MGMT promoter methylation status or IDH1/2 mutation status.CONCLUSION: Axitinib has single-agent activity in patients with recurrent GB; upfront combination of axitinib and LOM did not significantly increase progression-free or overall survival in patients with recurrent glioblastoma.Adding CCNU to axitinib after progression seems to result in improved PFS compared to upfront combination therapy. P08.
A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure
Authors: Sylvain Thepot, Simone Boehrer, Thomas Prebet, Odile Beyne-Rauzy, E. Wattel, Jacques Delaunay, Emmanuel Raffoux, Francois Dreyfus, Stefan Wickenhauser, Mathilde Hunault-Berger, Fatiha Chermat, Pierre Fenaux, Lionel Ades
Journal: Blood (2012)
OP0177 Ultrasound in The Management of Rheumatoid Arthritis: Results from The Randomized Controlled Arctic Trial: Table 1
Authors: E.A. Haavardsholm, A.-B. Aga, I.C. Olsen, S. Lillegraven, H.B. Hammer, T. Uhlig, H. Fremstad, T.M. Madland, Å.S. Lexberg, H. Haukeland, E. Rødevand, C. Høili, H. Stray, A.N. Bendvold, I.J.W. Hansen, G. Bakland, L.B. Nordberg, D.V.D. Heijde, T.K. Kvien
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Application of ultrasound (US) in the management of patients with rheumatoid arthritis (RA) is rapidly growing. <h3>Objectives</h3> The randomized controlled ARCTIC trial (ClinicalTrials.gov NCT01205854) examined if the use of a treatment strategy based on structured US assessment<sup>1</sup> would lead to improved outcomes in RA, compared to a conventional strategy based on clinical and laboratory assessments alone. <h3>Methods</h3> Newly diagnosed DMARD naïve RA patients were randomized 1:1 to A) an ultrasound tight control (UTC) strategy targeting clinical and imaging remission (no ultrasound power-Doppler signal) or B) a conventional tight control (CTC) strategy targeting clinical remission. Patients in both arms were treated according to the same DMARD escalation strategy, starting with MTX, then triple therapy MTX/SSZ/HCQ, then biologic DMARD if target was not reached. The primary endpoint was the proportion of patients with a combination between 16 and 24 months of clinical remission, no swollen joints and non-progression of radiographic joint damage. <h3>Results</h3> A total of 238 patients were randomized, and patients with at least one follow-up visit were included in the full analysis set (UTC n=118, CTC n=112). Twenty-six patients (22.0%) in the UTC arm and 21 patients (18.8%) in the CTC arm reached the primary endpoint (mean difference 3.3%; 95%CI -7.1% to 13.7%). No significant differences were found between the groups for the components of the primary outcome, and secondary endpoints were similar (table). <h3>Conclusions</h3> The implementation and systematic use of ultrasound in the follow-up of early RA patients treated with an aggressive treat-to-target strategy is not justified based on the results of the ARCTIC trial. <h3>References</h3> Hammer HB et al Ann Rheum Dis 2011 <h3>Disclosure of Interest</h3> E. Haavardsholm Grant/research support from: Pfizer, MSD, UCB, AbbVie, Roche, A.-B. Aga: None declared, I. Olsen: None declared, S. Lillegraven: None declared, H. Hammer Consultant for: AbbVie, Pfizer, BMS, Roche, UCB, T. Uhlig: None declared, H. Fremstad: None declared, T. Madland: None declared, Å. Lexberg: None declared, H. Haukeland Consultant for: UCB, AbbVie, E. Rødevand: None declared, C. Høili: None declared, H. Stray: None declared, A. Bendvold: None declared, I. Hansen: None declared, G. Bakland Consultant for: AbbVie, Pfizer, L. Nordberg: None declared, D. Heijde: None declared, T. Kvien: None declared
FRI0135 Increased Intrinsic Brain Connectivity between Affective Pain Processing Regions and Bilateral Sensorimotor Cortex in RA Patients Compared To Healthy Controls
Authors: J. Lampa, P. Flodin, S. Martinsen, R. Altawil, E. Waldheim, E. Kosek, P. Fransson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is commonly accompanied by pain that is discordant with the degree of peripheral pathology. Very little is known about the cerebral processes involved in pain processing in RA. <h3>Objectives</h3> To investigate resting state brain connectivity associated with prolonged pain in RA. <h3>Methods</h3> 24 RA subjects and 19 matched controls were compared with regard to both behavioral measures of pain perception and resting-resting state fMRI data acquired subsequently to fMRI sessions involving pain stimuli. The resting-state fMRI brain connectivity was investigated using 159 seed regions located in cardinal pain processing brain regions. Additional principal component based multivariate pattern analysis of the whole brain connectivity pattern was carried out in a data driven analysis to localize group differences in functional connectivity. <h3>Results</h3> When RA patients were compared to controls, we observed significantly lower pain resilience for pressure on the affected finger joints (i.e. P50-joint) and an overall heightened level of perceived global pain in RA patients. Relative to controls, RA patients displayed increased brain connectivity predominately for the supplementary motor areas, mid-cingulate cortex and the primary sensorimotor cortex. Additionally, we observed an increase in brain connectivity between the insula and prefrontal cortex as well as between anterior cingulate cortex and occipital areas for RA patients. None of the group differences in brain connectivity were significantly correlated with behavioral parameters. <h3>Conclusions</h3> Our study provides experimental evidence of increased connectivity between frontal midline regions that are implicated in affective pain processing and bilateral sensorimotor regions in RA patients. <h3>Disclosure of Interest</h3> None declared
PTU-027 Colonoscopy Withdrawal Time in Non-Screening Colonoscopies. 6 Minutes or Not?
Authors: M El-Feki, R Wilson, A Hopper, MH Thoufeeq
Journal: Gut (2016)

<h3>Introduction</h3> Several studies have shown that, in screening colonoscopies, ADR is significantly related to endoscopists with a colonoscopy withdrawal time (CWT).<sup>1</sup> A CWT of more than than 6 minutes is recommended. Studies have also demonstrated that if the endoscopists aware of being monitored they might increase their CWT (the Hawthorne effect). The bowel cancer screening program actively monitors the CWT of endoscopists to ensure that all colonoscopies are of adequate quality but non-screening colonoscopies are not routinely monitored in the same way. <h3>Methods</h3> We prospectively looked at 19 endoscopists’ practice of colonoscopy of 210 procedures. This included 10 gastroenterologists and 9 non-gastroenterologists. We calculated their withdrawal time by looking at time duration between caecal and rectal retroflexion images. Exclusion criteria included procedures that were incomplete, poor preparation, screening patients, patients in whom polyps were found and planned therapeutic procedures. In order to avoid ‘Hawthorne effect’, endoscopists were unaware that they were being monitored. Subsequent to that we did a statistical analysis to see if withdrawal time correlated with adenoma detection rate. The ADR was available from the unit’s annual endoscopy audit. <h3>Results</h3> CWT was less than 6 minutes in 20% of procedures. The mean CWT varied greatly among endoscopists. The mean CWT was significantly longer where the endoscopist was a gastroenterologist rather than a non-gastroenterologist (p = 0.0003). All of the endoscopists that had a mean CWT less than 6 minutes were part of the non-gastroenterologist group. Although we found ADR levels lower in mean CWT of less than 6 minutes and a positive correlation, this however did not reach statistical significance(p = 0.62). <h3>Conclusion</h3> In our study we found in majority of the non-screening colonoscopies, withdrawal time was more than the recommended 6 minutes. Statistically significant correlation between ADR and withdrawal in non-screening colonoscopies may be achieved by participating in large multi-centred studies. <h3>Reference</h3> 1 Lee TJ, Blanks RG, Rees CJ, Wright KC, Nickerson C, Moss SM, Chilton A, Goddard AF, Patnick J, McNally RJ, Rutter MD. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel cancer screening programme in England. <i>Endoscopy</i> 2013;<b>45</b>(1):20–6. <h3>Disclosure of Interest</h3> None Declared
B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.
Authors: Maria K. Angelopoulou, Maria Papakonstantinou, Flora N. Kontopidou, Maria N. Dimopoulou, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, Christina Kalpadakis, Styliani Kokoris, Evangelia M. Dimitriadou, Zacharoula Galani, Sotirios Sachanas, Padelis Tsirkinidis, Marie-Christine Kyrtsonis, Penelope Korkolopoulou, Panayiotis Panayiotidis, Gerassimos A. Pangalis
Journal: Blood (2006)
Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Authors: Susan D Mathias, Xiaoyan Li, Melissa Eisen, Nancy Carpenter, Ross D Crosby, Victor S. Blanchette
Journal: Blood (2015)
Techniques of Selective Cannulation and Sphincterotomy
Authors: A Maydeo, D Borkar
Journal: Endoscopy (2003)

Selective access into the desired duct followed by incision of the sphincter, i. e. sphincterotomy, forms the cornerstone of any endoscopic intervention within the pancreaticobiliary system. The apprehensive beginner’s performance and hesitance is aggravated by ignorance of ampullary anatomy and he considers selective cannulation to be the greatest hurdle. An understanding of ampullary morphology and its variations is vital in achieving selective cannulation. Technological advances have assisted in the form of development of better accessories, progressing from ”immovable” catheters to movable cannulae and to single-, double-, and even triple-lumen sphincterotomes. Orientation along the long axis of the bile duct ensures access and avoids inadvertent and hazardous manipulation of the pancreatitic duct. Using guide wires, especially the ‘angulated-tip’ glide wire improves cannulation successs rates considerably. Precut accessotomy complements wire-guided selective cannulation, and can be used analogously to a controlled surgical incision to facilitate cannulation of the desired system after deroofing the papilla layer by layer. Published data have validated its role, demonstrating high efficacy and minimal complications when it is properly performed. Biliary sphincterotomy, using the right mode of blended current in the 11–12 o’clock direction and with the tip of the sphincterotome wire, provides a clean and bloodless splitting open of the sphincter of Oddi. Pancreatic precut, over-the-stent papillotomy and sphincterotomy over a guide wire have all been proven to be safe and effective measures, in large groups of patients. In special situations, such as where there are impacted stones or ampullary lesions, needle-knife infundibulotomy achieves reliable access. Techniques such as saline infiltration into the papilla and subtle body movements to re-position the scope enable biliary cannulation in difficult situations. Alterations in anatomy, for instance post Billroth II gastrectomy, no longer discourage the endoscopist from attempting intervention. Application of knowledge of reverse anatomy, specially designed instruments, and adherence to the proper technique improves success in these patients. Our experience of 9000 sphincterotomies over the past 12 years with minimal morbidity stands proof to the principles and techniques highlighted in this monograph. We recommend these to all aspiring endoscopists, with the assurance of improved technical success when they are implemented.